D. Oh

发表

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

A. Spira, S. Klempner, J. Chao, 2022, ESMO open.

Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study.

P. Ascierto, W. Miller, A. Marabelle, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)

J. Ajani, G. Ku, Yeul-Hong Kim, 2021, Annals of Oncology.

SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset

A. Drilon, J. Berlin, Ruifeng Xu, 2021, Annals of Oncology.

Management of gastric lymphoma with chemotherapy alone

T. Kim, D. Heo, D. Oh, 2005, Leukemia & lymphoma.

Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study.

L. Coussens, M. Reni, E. Van Cutsem, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

M. Reni, E. Van Cutsem, H. Algül, 2019, Annals of Oncology.

O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202

E. Van Cutsem, M. Borad, G. Abou-Alfa, 2022, Annals of Oncology.

P. Ascierto, W. Miller, M. Maio, 2021, Annals of Oncology.

Tolerability and single dose pharmacokinetics of a new PDE5 inhibitor, DA‐8159 in healthy male subjects

S. Yi, I. Jang, K. Hong, 2003 .

SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma

C. Lopez, H. Kindler, H. Barak, 2020, Annals of Oncology.

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

M. Lowery, L. Wyrwicz, F. Rivera, 2023, Annals of Oncology.

1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer

M. Reni, G. Tortora, D. Hochhauser, 2021, Annals of Oncology.

Targeted RNA interference of phosphatidylinositol 3‐kinase p110‐β induces apoptosis and proliferation arrest in endometrial carcinoma cells

S. Lee, H. Kim, S. W. Lee, 2007, The Journal of pathology.

51P Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)

F. Meric-Bernstam, J. Furuse, J. Bridgewater, 2021, Annals of Oncology.

209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors

S. Loi, D. Sabanathan, M. Beeram, 2021, Annals of Oncology.

Identification of influence of CYP3A5 genetic polymorphism in tacrolimus pharmacokinetics assessed from routine TDM data using population pharmacokinetic approach

S. Yi, I. Jang, K. Hong, 2003 .

460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

A. Tolcher, K. Jhaveri, A. Spira, 2022, Annals of Oncology.

LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

M. Millward, C. Ferté, Chiung-Ying Liao, 2022, Annals of Oncology.

SO-31 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset

A. Drilon, C. Mussi, J. Berlin, 2022, Annals of Oncology.

56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

H. Burris, A. Avallone, S. Qin, 2022, Annals of Oncology.

1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study

M. Reni, J. Tabernero, T. Bekaii-Saab, 2021, Annals of Oncology.

SO-7 Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial

Y. Janjigian, H. V. van Laarhoven, S. Rha, 2022, Annals of Oncology.

P-53 A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma

S. Piha-Paul, V. Arrazubi, S. Rha, 2022, Annals of Oncology.

68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

V. Guthrie, S. Qin, D. Tougeron, 2022, Annals of Oncology.

57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

G. Vaccaro, R. Gillmore, K. Heider, 2022, Annals of Oncology.

O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

P. Potemski, D. Tougeron, C. Morizane, 2022, Annals of Oncology.